People: Haemonetics Corp (HAE)

HAE on New York Consolidated

38.11USD
24 Dec 2014
Price Change (% chg)

$0.30 (+0.79%)
Prev Close
$37.81
Open
$37.72
Day's High
$38.22
Day's Low
$37.47
Volume
90,558
Avg. Vol
251,815
52-wk High
$43.60
52-wk Low
$29.86

Search Stocks

Summary

Name Age Since Current Position

Richard Meelia

65 2011 Non-Executive Independent Chairman of the Board

Brian Concannon

56 2009 President, Chief Executive Officer, Director

Christopher Lindop

56 2013 Chief Financial Officer, Executive Vice President - Business Development

Peter Allen

55 2011 President - Global Plasma

David Helsel

50 2013 Executive Vice President - Global Manufacturing

Jonathan White

54 2013 Chief Science and Technology Officer

Susan Hanlon

46 2008 Chief Accounting Officer, Vice President - Finance

Sandra Jesse

61 2011 Vice President, Chief Legal Officer

Susan Foote

67 2004 Independent Director

Ronald Gelbman

66 2011 Independent Director

Pedro Granadillo

67 2004 Independent Director

Mark Kroll

61 2006 Independent Director

Ronald Merriman

69 2005 Independent Director

Ellen Zane

62 2012 Independent Director

Biographies

Name Description

Richard Meelia

Mr. Richard J. Meelia is Non-Executive Independent Chairman of the Board of Haemonetics Corporation. Since July 2007 to his retirement in July 2011, Chairman, President, and Chief Executive Officer of Covidien plc, a global healthcare products company. From 1995 to July 2007, President of Tyco Healthcare, the healthcare business which was spun off from its parent company, Tyco International, to form Covidien plc in July 2007 and from 1991 to 1995, Group President of Kendall Healthcare Products Company, a $450 million healthcare business, which was an early component of the Tyco Healthcare business. From 1987 to 1990, President of Infusaid, Inc., a division of Pfizer and from 1973 to 1987, in several different roles including Vice President of Sales and Marketing at American Hospital Supply Corporation/Kendall McGaw. Currently, member of the Board of Directors of Triangle, Inc., a career empowerment network for people with disabilities, member of the Board of Governors of Tufts Medical Center, and member of the Board of Trustees of St. Anselm College and Massachusetts Hospital School. From 2008 - 2012 Chairman of the Board of Directors of Covidien, plc.

Brian Concannon

Mr. Brian P. Concannon is President, Chief Executive Officer, Director of Haemonetics Corporation. He joined Haemonetics in 2003 as President of the Patient Division. He was promoted to President of Global Markets in 2006 and then to Chief Operating Officer in 2007. In April 2009, he was promoted to President and Chief Executive Officer, and elected to the Haemonetics Board of Directors. Immediately prior to joining Haemonetics, Mr. Concannon was President of the Northeast Region at Cardinal Health Medical Products and Services where he was employed since 1998. From 1985 to 1998, he was employed by American Hospital Supply Corporation, Baxter Healthcare Corporation, and Allegiance Healthcare in a series of sales and operatiaons management positions of responsibility.

Christopher Lindop

Mr. Christopher J. Lindop is Chief Financial Officer, Executive Vice President - Business Development of Haemonetics Corporation. He joined Haemonetics in January of 2007 as Chief Financial Officer. In 2007, Mr. Lindop assumed responsibility for business development. Prior to joining Haemonetics, he was Chief Financial Officer at Inverness Medical Innovations, a rapidly growing global developer of advanced consumer and professional diagnostic products from 2003 to 2006. Prior to this, Mr. Lindop was a Partner in the Boston offices of Ernst & Young LLP and Arthur Andersen LLP.

Peter Allen

Mr. Peter M. Allen is President - Global Plasma of Haemonetics Corporation. He joined Company in 2003 as President, Donor Division. In March 2008, Mr. Allen was appointed Chief Marketing Officer. In October 2011, he was promoted to President of Global Plasma. Prior to joining Haemonetics, Mr. Allen was Vice President of The Aethena Group, a private equity firm providing services to the global healthcare industry. From 1998 to 2001, he held various positions including Vice President of Sales and the Oncology Business at Syncor International, a provider of radiopharmaceutical and comprehensive medical imaging services. Previously, Mr. Allen held executive level positions in sales, marketing, and operations in DataMedic, Inc., Enterprise Systems, Inc./HBOC, and Robertson Lowstuter, Inc. Mr. Allen has also worked in sales and marketing at American Hospital Supply Corporation and Baxter International, Inc.

David Helsel

Mr. David D. Helsel is an Executive Vice President - Global Manufacturing of Haemonetics Corporation. He joined Haemonetics as Vice President of Global Manufacturing in March 2012, and is responsible for worldwide oversight of the Company’s manufacturing and supply chain organizations. Mr. Helsel was previously with Covidien, Ltd. for 16 years, where he most recently was Vice President of Operations for the Surgical Solutions global business unit. During his tenure with Covidien, his previous roles included Vice President of Operations for the Medical Supplies segment and Global Director of Operational Excellence – Manufacturing. Mr. Helsel holds a Bachelor of Science degree in Mechanical Engineering from LeTourneau University.

Jonathan White

Dr. Jonathan White is Chief Science and Technology Officer of Haemonetics Corporation. Dr. White joined Haemonetics in 2008 as Vice President of Research and Development. Dr. White joined Haemonetics from Pfizer where he held a number of roles including Chief Information Officer. He previously worked at McKinsey and Company in New York. Dr. White is a Fellow of the Royal College of Surgery in England.

Susan Hanlon

Ms. Susan Hanlon is Chief Accounting Officer, Vice President - Finance of Haemonetics Corporation. She joined the Company in 2002 as Vice President and Corporate Controller. In 2004, she was promoted to Vice President Planning and Control, and in 2008, Ms. Hanlon was promoted to Vice President Finance. She presently has responsibility for Controllership, Financial Planning, Tax, and Treasury. Prior to joining Haemonetics, Ms. Hanlon was a partner with Arthur Andersen LLP in Boston.

Sandra Jesse

Ms. Sandra Jesse is Vice President, Chief Legal Officer of Haemonetics Corporation., since September 2011. She is responsible for the company’s world-wide Legal, Compliance and Corporate Audit and Controls groups. Ms. Jesse was previously the Executive Vice President and Chief Legal Officer of Blue Cross Blue Shield of Massachusetts, a Partner in the Boston law firm of Choate, Hall and Stewart, and Press Secretary for United States Congressman, Lee Hamilton. She has served on a number of Boards of Directors, including the New England Legal Foundation, Longy School of Music, Boston Harbor Island Alliance and the Landmark School. Ms. Jesse is a former President of the Boston Bar Foundation.

Susan Foote

Ms. Susan Bartlett Foote is an Independent Director of Haemonetics Corporation. From 2009 to Present, Professor Emeritus, Division of Health Policy and Management for the School of Public Health, University of Minnesota. From 1999 to 2009, Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota. 1999 to 2006, Associate Professor and from 1999 to 2005 Division Head and from 1996 to 1999, President, Public Policy Partners, a health policy consulting firm. From 1995 a Partner in the law firm of Dorsey & Whitney. From 1991 to 1994, a Senior Health Policy Analyst for the United States Senate and from 1982 to 1993, Associate Professor of Business & Public Policy at the University of California at Berkeley. Currently, member of the California State Bar Association; board of Directors of Banner Health; and Board Member of the Medical Technology Leadership Forum.

Ronald Gelbman

Mr. Ronald G. Gelbman is an Independent Director of Haemonetics Corporation. From 1998 to his retirement in 2000, he was Johnson & Johnson Worldwide Chairman of the Health Systems and Diagnostics Group and member of the Executive Committee. From 1994 to 1998 he was Johnson & Johnson Worldwide chairman, Pharmaceuticals and Diagnostics and member of the Executive Committee and from 1972 to 1994 various senior level positions throughout the Johnson and Johnson organization. Currently he is a member of the Board of Directors of Clockwork Home Services, a private company; and the SunTrust Southwest Florida Board of Advisors; Trustee at Rollins College, Chair of Sarasota YMCA; and Chair of Out-of-Door Academy College Preparatory School.

Pedro Granadillo

Mr. Pedro P. Granadillo is an Independent Director of Haemonetics Corporation. Currently Chairman of the Board at AuraBiosciences, a private biotechnology company. From 2008 to 2010, Chairman of the Board, Tigris Pharmaceuticals, Inc., a biotechnology company. From 1998 to his retirement in 2004, Senior Vice President of Eli Lilly & Company with responsibility for manufacturing, quality and human resources and member of the Executive Committee. From 1993 to 1998, Vice President, Human Resources at Eli Lilly & Company and from 1970 to 1998 various senior positions at Eli Lilly & Company in manufacturing including thirteen years in Europe. Currently, member of the Board of Directors of Nile Therapeutics, a pharmaceutical company, Dendreon Corporation, a biotechnology company, and NPS Pharmaceuticals, a biotechnology company.

Mark Kroll

Dr. Mark W. Kroll, Ph.D., is an Independent Director of Haemonetics Corporation. From 1995 to his retirement in 2005, with St. Jude Medical, Inc.; senior level positions including 2001 to 2005 as Chief Technology Officer of the Cardiac Rhythm Management Division and 1999 to 2001 as Senior Vice President for Technology and Design. Adjunct Full Professor of Biomedical Engineering at the California Polytechnic State University (emeritus), and Adjunct Full Professor of Biomedical Engineering at the University of Minnesota. Awarded 2010 Career Achievement Award in Biomedical Engineering which is the highest international award in biomedical engineering. Currently, serves on the Board of Directors for TASER International, Inc., a safety technologies company, and NewCardio Inc., a electrocardiography company.

Ronald Merriman

Mr. Ronald L. Merriman is an Independent Director of Haemonetics Corporation. Retired Vice Chair of KPMG where his role was leader of the health care and life sciences business as well as he held various positions including membership on the Executive Management Committee, managing partner of the firm’s Global Health Care Business, Board Member, and Senior Partner. From 2000 to 2003 he was Managing Director and Member of the Office of the Chair at O’Melveny & Myers LLP and from 1999 to 2000 Executive Vice President of Carlson Wagonlit Travel. From 1967 to 1997 he was responsible positions at KPMG including Vice Chair of the Executive Management Committee, managing partner of the firm’s Global Health Care Business, Board Member, and Senior Partner. Currently is a member of the Board of Directors and chair of the Audit Committee of Aircastle Limited, a publicly traded aircraft leasing company; member of the Board of Directors and chair of the Audit Committee of Pentair, Inc., a publicly traded global diversified industrial company and a member of the Board, Governance and Nominating Committee and Audit Committee of Realty Income Corporation, a publicly traded real estate investment trust. Previously he served as a director of Cardio Dynamics International from July 2003 to July 2005 and as a director of Corautus Genetics, Inc. from April 2004 to May 2005.

Ellen Zane

Ms. Ellen M. Zane is an Independent Director of Haemonetics Corporation., since July 27, 2012. Ms. Zane was formerly President & CEO of Tufts Medical Center & Floating Hospital for Children in Boston from 2004 until her retirement in 2011 and currently serves as Vice Chairman of the Board of Trustees. In addition to her role as Vice Chairman and previous roles as President and CEO, Ms. Zane has been an Assistant Professor in the Department of Medicine, Division of Clinical Care Research, since 2004 and is an Assistant Professor of Public Health and Community Medicine at The Tufts University School of Medicine. Additionally, she is an Adjunct Assistant Professor of Health Policy and Management at The Harvard School of Public Health. Prior to joining Tufts Medical Center, Ms. Zane, who has over 30 years of healthcare industry experience, was Network President of Partners Healthcare System from 1994 to 2004. She was Chief Executive Officer and previously Chief Operating Officer of Quincy Hospital from 1987 to 1994 and held a number of senior professional services leadership positions with Morton Hospital & Medical Center from 1979 to 1987 and Lawrence General Hospital from 1975 to 1979. Ms. Zane serves on the Boards of Directors of Brooks Automation, Lincare Holdings Inc., Parexel International Corporation, Century Capital Management, George Washington University, and the Health Policy and Management Council of the Harvard School of Public Health. She has an MA degree from Catholic University of America, a BA degree from George Washington University and honorary doctorate degrees from Bentley University, Stonehill College and Curry College.

Basic Compensation

Name Fiscal Year Total

Richard Meelia

--

Brian Concannon

5,977,600

Christopher Lindop

2,294,940

Peter Allen

2,077,910

David Helsel

1,385,620

Jonathan White

1,767,900

Susan Hanlon

--

Sandra Jesse

--

Susan Foote

--

Ronald Gelbman

--

Pedro Granadillo

--

Mark Kroll

--

Ronald Merriman

--

Ellen Zane

--
As Of 28 Mar 2014

Options Compensation

Name Options Value

Richard Meelia

0 0

Brian Concannon

279,000 6,760,550

Christopher Lindop

123,566 1,558,750

Peter Allen

261,488 6,440,280

David Helsel

0 0

Jonathan White

0 0

Susan Hanlon

0 0

Sandra Jesse

0 0

Susan Foote

0 0

Ronald Gelbman

0 0

Pedro Granadillo

0 0

Mark Kroll

0 0

Ronald Merriman

0 0

Ellen Zane

0 0
Search Stocks